Nurix Therapeutics Announces Presentations at the 64th American Society of Hematology (ASH) Annual Meeting

Author's Avatar
Nov 03, 2022

Nurix to provide a clinical update from the ongoing Phase 1 trial of NX-2127 in patients with hematologic malignancies